$INTI
Inhibitor Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000119312521161385 Filed on May 14, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $163.9K $53.03K $288.0K
YoY Change -43.1% -82.0% -51.58%
% of Gross Profit
Research & Development $3.880K $0.00 $97.46K
YoY Change -96.02% -100.0% -50.47%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $167.8K $55.74K $385.4K
YoY Change -56.48% -91.26% -51.31%
Operating Profit -$167.8K -$385.4K
YoY Change -56.48% -51.31%
Interest Expense -$1.690K -$110.00 $1.030K
YoY Change -264.08% -105.37% -80.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$127.8K -$55.85K -$384.4K
YoY Change -66.74% -91.22% -51.11%
Income Tax
% Of Pretax Income
Net Earnings -$127.8K -$55.85K -$384.4K
YoY Change -66.74% -91.22% -51.11%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$340.40 -$149.50 -$1.038K
COMMON SHARES
Basic Shares Outstanding 375.9M 373.6M 370.4M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q4 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $84.19K $75.06K $302.7K
YoY Change -72.19% -90.66% -73.23%
Cash & Equivalents $84.19K $75.06K $302.7K
Short-Term Investments
Other Short-Term Assets $36.79K $32.29K $48.24K
YoY Change -23.74% -23.93% 4.53%
Inventory
Prepaid Expenses $36.79K $32.29K $48.24K
Receivables
Other Receivables
Total Short-Term Assets $121.0K $107.4K $350.9K
YoY Change -65.53% -87.31% -70.18%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $17.09K $24.41K $46.38K
YoY Change -63.16% -54.55% -38.71%
Total Long-Term Assets $17.09K $24.41K $46.38K
YoY Change -63.16% -54.55% -38.71%
TOTAL ASSETS
Total Short-Term Assets $121.0K $107.4K $350.9K
Total Long-Term Assets $17.09K $24.41K $46.38K
Total Assets $138.1K $131.8K $397.3K
YoY Change -65.25% -85.36% -68.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $322.0K $269.4K $154.2K
YoY Change 108.76% -14.73% -37.08%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $52.00K $30.04K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $432.6K $425.4K $345.9K
YoY Change 25.07% -1.32% 6.49%
LONG-TERM LIABILITIES
Long-Term Debt $104.0K $66.56K $0.00
YoY Change
Other Long-Term Liabilities $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 100.0%
Total Long-Term Liabilities $3.104M $3.067M $3.000M
YoY Change 3.47% 2.22% 100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $432.6K $425.4K $345.9K
Total Long-Term Liabilities $3.104M $3.067M $3.000M
Total Liabilities $3.537M $3.492M $3.346M
YoY Change 5.7% 1.77% 83.36%
SHAREHOLDERS EQUITY
Retained Earnings -$57.35M -$57.17M -$56.35M
YoY Change 1.78% 2.25% 4.7%
Common Stock $49.99M $49.85M $49.44M
YoY Change 1.12% 0.87% 0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.399M -$3.360M -$2.949M
YoY Change
Total Liabilities & Shareholders Equity $138.1K $131.8K $397.3K
YoY Change -65.25% -85.36% -68.28%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020 Q1
OPERATING ACTIVITIES
Net Income -$127.8K -$55.85K -$384.4K
YoY Change -66.74% -91.22% -51.11%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$91.87K -$16.65K -$501.1K
YoY Change -81.67% -97.07% -48.76%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 101.0K 55.00K 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -91.87K -16.65K -501.1K
Cash From Investing Activities
Cash From Financing Activities 101.0K 55.00K 0.000
Net Change In Cash 9.130K 38.35K -501.1K
YoY Change -101.82% -106.75% -2376.72%
FREE CASH FLOW
Cash From Operating Activities -$91.87K -$16.65K -$501.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138066
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131759
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84189
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75059
CY2021Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
36792
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
32292
CY2021Q1 us-gaap Assets Current
AssetsCurrent
120981
CY2020Q4 us-gaap Assets Current
AssetsCurrent
107351
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
17085
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24408
CY2021Q1 us-gaap Assets
Assets
138066
CY2020Q4 us-gaap Assets
Assets
131759
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
321985
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
269416
CY2021Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
49315
CY2020Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
100822
CY2021Q1 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
0
CY2021Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9310
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
25124
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
432610
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
425406
CY2021Q1 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
0
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3000000
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
37588
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
37364
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49952631
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
49814043
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57349629
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57172476
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-3398544
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-384417
CY2021Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49315
CY2020Q1 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
49863
CY2021Q1 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-177153
CY2020Q1 inti Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-434280
CY2021Q1 us-gaap Revenues
Revenues
0
CY2020Q1 us-gaap Revenues
Revenues
0
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3880
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97455
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
163873
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
287987
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
167753
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
385442
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-167753
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-385442
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
0
CY2020Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1025
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-127838
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
375527841
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
370446185
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-3360203
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
37990
CY2021Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49315
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
16819
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
49863
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-2948596
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-2531135
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-127838
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-384417
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
37990
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
16819
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2823
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1534
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
36755
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-135064
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91870
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-501128
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
101000
CY2020Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
803816
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
302688
CY2021Q1 us-gaap Stock Issued1
StockIssued1
100822
CY2020Q1 us-gaap Stock Issued1
StockIssued1
0
CY2021Q1 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49315
CY2020Q1 inti Accrued But Unpaid Dividends
AccruedButUnpaidDividends
49863
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 inti Royalty Rate On Net Sales
RoyaltyRateOnNetSales
0.09
CY2021Q1 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
11556
CY2020Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
30044
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2253623
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
375876361
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
373635873
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
375876361
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
373635873
CY2021Q1 us-gaap Line Of Credit
LineOfCredit
104000
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
55000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9130
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-501128
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Estimates </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
Inhibitor Therapeutics, Inc.
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
375876361
CY2021Q1 us-gaap Related Party Transaction Due From To Related Party Current
RelatedPartyTransactionDueFromToRelatedPartyCurrent
-52000
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1685
CY2020Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0
CY2021Q1 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
CY2020Q1 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
0
CY2021Q1 us-gaap Stock Issued During Period Value Dividend Reinvestment Plan
StockIssuedDuringPeriodValueDividendReinvestmentPlan
100822
CY2021Q1 us-gaap Gain Loss On Sales Of Loans Net
GainLossOnSalesOfLoansNet
41600
CY2021Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
0
CY2021Q1 us-gaap Liabilities
Liabilities
3536610
CY2020Q4 us-gaap Liabilities
Liabilities
3491962

Files In Submission

Name View Source Status
0001193125-21-161385-index-headers.html Edgar Link pending
0001193125-21-161385-index.html Edgar Link pending
0001193125-21-161385.txt Edgar Link pending
0001193125-21-161385-xbrl.zip Edgar Link pending
d158922d10q.htm Edgar Link pending
d158922dex311.htm Edgar Link pending
d158922dex312.htm Edgar Link pending
d158922dex321.htm Edgar Link pending
d158922dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inti-20210331.xml Edgar Link completed
inti-20210331.xsd Edgar Link pending
inti-20210331_cal.xml Edgar Link unprocessable
inti-20210331_def.xml Edgar Link unprocessable
inti-20210331_lab.xml Edgar Link unprocessable
inti-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending